Gland Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


50,655	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3,359	3,359	2,556	357	1,909
243	243	269	320	3.8
47,540	—	—	—	—
−3,116	−3,116	−2,287	−37.3	−1,905
₹2,885.39	—	—	—	—

10,601	10,601	9,420	9,044	7,963
2.3%	2.3%	2.9%	3.5%	0.0%
0.01×	—	—	—	—

7.07×	—	—	—	—
27.15×	—	—	—	—
36.09×	—	—	—	—
88.54×	—	—	—	—
6,725	6,431	5,617	5,665	3,625
1,751	1,630	1,269	1,333	1,025
1,317	1,206	891	989	878
—	1,031	915	997	364
537	537	521	599	141
—	527	510	591	139
—	494	394	398	223

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹3,074.50

Gland Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹50,655 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	50,655.5
- Cash, Equiv & ST Investments	1,908.9	357.1	2,556.2	3,359.1	3,359.1
+ Total Debt	3.8	319.8	269.2	243.4	243.4
Enterprise Value	—	—	—	—	47,539.7
Net Debt (memo)	-1,905.1	-37.3	-2,287.0	-3,115.7	-3,115.7
EV per Share	—	—	—	—	2,885.39

Total Capital	7,962.5	9,043.6	9,420.0	10,601.3	10,601.3
Total Debt/Total Capital	0.05	3.54	2.86	2.30	2.30
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	7.07
EV/EBITDA	—	—	—	—	27.15
EV/EBIT	—	—	—	—	36.09
EV/Free Cash Flow	—	—	—	—	88.54
Reference Items — Trailing FY Values
Sales	3,624.6	5,664.7	5,616.5	6,430.7	6,725.3
EBITDA	1,024.8	1,333.1	1,268.9	1,629.5	1,751.1
EBIT	878.0	988.5	891.1	1,205.9	1,317.3
Operating Cash Flow	364.0	996.8	914.7	1,031.4	—
Free Cash Flow	140.8	598.5	520.6	537.0	537.0
FCFF (free cash flow to the firm)	139.2	591.1	510.1	527.3	—
Capital Expenditure	223.1	398.3	394.2	494.4	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.